A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
NCT ID: NCT00424047
Last Updated: 2017-10-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
351 participants
INTERVENTIONAL
2003-01-01
2013-11-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CC-5013 plus dexamethasone
Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.
CC-5013 plus dexamethasone
25 mg daily for 21 days every 28 days.
Dexamethasone plus placebo
Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
Dexamethasone plus Placebo
Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CC-5013 plus dexamethasone
25 mg daily for 21 days every 28 days.
Dexamethasone plus Placebo
Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1, or 2
* Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug
Exclusion Criteria
* Pregnant or lactating females
* The development of a desquamating rash while taking thalidomide
* Use of any standard/experimental anti-myeloma therapy within 28 days of randomization or use of any experimental non-drug therapy within 56 days of initiation of drug treatment
* Laboratory abnormalities: Absolute neutrophil count less than 1,000 cells/mm3
* Laboratory abnormalities: Platelet count \< 75,000/mm3
* Laboratory abnormalities: Serum creatinine \> 2.5 mg/dL
* Laboratory abnormalities: Serum Serum glutamic oxaloacetic transaminase (SGOT)/Aspartate aminotransferase (AST) or Serum glutamic pyruvic transaminase (SGPT)/Alanine aminotransferase (ALT) \> 3.0 x upper limit of normal
* Laboratory abnormalities: Serum total bilirubin \> 2.0 mg/dL
* Prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for ≥ 3 years.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Knight, MD
Role: STUDY_DIRECTOR
Celgene Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Peter MacCallum Cancer Centre Divsion of Haematology/Medical Oncology
East Melbourne, Victoria, Australia
The Alfred Hospital
Prahran, Victoria, Australia
Border Medical Oncology
Wodonga, Victoria, Australia
Box Hill Hospital
Box Hill, , Australia
Frankston Hospital Oncology Research
Frankston, , Australia
Royal Brisbane Hospital
Herston, , Australia
The Royal Melbourne Hospital
Parkville, , Australia
Mater Public Hospital
South Brisbane, , Australia
University Hospital of Salzburg St Johanns Spital
Salzburg, , Austria
Wilhelminenspital
Vienna, , Austria
CHU Saint-Luc
Brussels, , Belgium
UZ Gasthuisberg
Leuven, , Belgium
Centre Hospitalier Lyon Sud
Chemin Grand Revoyet, , France
Hopital Claude Huriez
Lille, , France
Centre Hospitalier Hotel-Dieu
Nantes, , France
Hopital Saint-Loius
Paris, , France
Chu de Bordeaux Groupe Hospitalier Sud
Pessac, , France
CHU Purpan
Toulouse, , France
CHU Nancy - Hopital Brabois
Vandœuvre-lès-Nancy, , France
Universitaetsklinikum Charite
Berlin, , Germany
Universitatsklinik ChariteMedizinische Fakultaet der HumboldtUniversitaet zu Berlin
Berlin, , Germany
Universitaetsklinikum Dusseldorf Klinik fuer Haematologie
Düsseldorf, , Germany
Universitaetsklinkum Erlangen
Erlangen, , Germany
Klininkum der Johann-Wolfgang-Goethe-Universtat
Frankfurt am Main, , Germany
Universitaetsklinikum Heidelberg Medizinische Klinik und Poliklinik V
Heidelberg, , Germany
Klinikum der Univeristact Muenchen
München, , Germany
Universitatsklinik Muenster Medizinische Klinik A
Münster, , Germany
Universitaetsklinikum Tuebingen
Tübingen, , Germany
"Alexandras" General Hospital of Athens
Athens, , Greece
University Hospital GalwayHaematology Department
Galway, Co. Galway, Ireland
Belfast City HospitalHaematology Department
Belfast, , Ireland
Hope Directorate Haematology Oncology Service St. James Hospital
Dublin, , Ireland
MidWestern Regional Hospital
Limerick, , Ireland
Rambam Medical Center
Haifa, , Israel
Hadassah University Hospital
Jerusalem, , Israel
Tel Aviv Sourasky Medical Center Department of Hematology
Tel Aviv, , Israel
The Chaim Sheba Medical Center
Tel Litwinsky, , Israel
Policlinico Sant'Orsola-Malpighi
Bologna, , Italy
Azienda Ospedaliera San Martino
Genova, , Italy
Ospedale Niguarda Ca Granda
Milan, , Italy
Policlinico San Matteo
Pavia, , Italy
Univerita La Sapien
Roma, , Italy
Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista
Torio, , Italy
Policlinico Universitario a Gesttione diretta di Udine
Udine, , Italy
Institute of Internal Diseases University of Medicine
Gdansk, , Poland
University School of Medicine
Lublin, , Poland
Institute of Haematology and Blood Transfusion
Warsaw, , Poland
Hospital Clinic
Barcelona, , Spain
Hospital Universitario de la Princessa
Madrid, , Spain
Hospital Doce de Octubre
Madrid, , Spain
Clinica Universitaria de Navarra
Pamplona, , Spain
Hospital Universitario de Salamanca
Salamanca, , Spain
Hospital Universtario Marques de Valdecilla
Santander, , Spain
Sahlgrenska University Hospital Department of Hematology and Coagulation
Gothenburg, , Sweden
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, , Switzerland
Kantonsspital St. Gallen
Sankt Gallen, , Switzerland
Universitätsspital Zürich
Zurich, , Switzerland
Cherkassy Regional Oncology Center
Cherkassy, , Ukraine
Dnepropetrovsk City Clinical Hospital #4
Dnipro, , Ukraine
Kiev Bone Marrow Transplantation Center Bone Marrow Department
Kiev, , Ukraine
Institute of Hematology and Transfusiology of the UAMS Department of blood diseases
Kiev, , Ukraine
Institute of Blood Pathology and Transfusion Medicine of the UAMS Hematology Department
Lviv, , Ukraine
Institute of Blood Pathology and Transfusion Medicine of the UAMS
Lviv, , Ukraine
Odess Regional Clinical Hospital
Odesa, , Ukraine
Zhitomir Regional Clinical Hospital
Zhytomyr, , Ukraine
University College Hospital Trust
London, Bloomsbury, United Kingdom
Bristol Haematology and Oncology Centre
Bristol, , United Kingdom
Haematology Dept, 4th Floor Thomas Guy House
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. doi: 10.1056/NEJMoa070594.
San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):38-43. doi: 10.3816/CLML.2010.n.120.
Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010 Jan 1;28(1):132-5. doi: 10.1200/JCO.2009.23.0169. Epub 2009 Nov 9.
Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CC-5013-MM-010
Identifier Type: -
Identifier Source: org_study_id